Summary:
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study with Orticumab in Subjects with Moderate-to-Severe Psoriasis and Cardiometabolic risk factors
Qualified Participants Must:
• Male or Female age 30 and over
•
BMI ≥ 30
•
Diagnosed with Psoriasis
Qualified Participants May Receive:
Compensation up to $ 1175.00